U.S. markets open in 2 hours 54 minutes

DURECT Corporation (DRRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2650-0.0750 (-3.21%)
At close: 4:00PM EST

2.1500 -0.12 (-5.08%)
Pre-Market: 6:24AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.3400
Open2.3700
Bid2.1200 x 27000
Ask2.1800 x 2200
Day's Range2.2500 - 2.3900
52 Week Range0.9500 - 2.9600
Volume2,458,019
Avg. Volume2,041,498
Market Cap508.47M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.0500
Earnings DateNov 02, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock
    PR Newswire

    DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock

    DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, today announced the pricing of its underwritten public offering of 17,708,333 shares of its common stock (the "Offering") for gross proceeds of approximately $42,500,000, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by DURECT. The offering is expected to close on or about February 8, 2021, subject to customary closing conditions. In addition, DURECT has granted the underwriter for the Offering a 30-day option to purchase up to an additional 2,656,249 shares of its common stock.

  • DURECT Corporation Announces Proposed Offering of Common Stock
    PR Newswire

    DURECT Corporation Announces Proposed Offering of Common Stock

    DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, today announced that it is commencing an underwritten public offering of its common stock (the "Offering"). All of the shares to be sold in the Offering will be sold by DURECT, subject to customary closing conditions. In addition, DURECT intends to grant the underwriter for the Offering a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering.

  • MarketWatch

    Durect stock soars 34% after it gets FDA approval for surgical pain treatment

    Shares of Durect Corp. gained 34.3% in premarket trading on Tuesday after the company said its drug, Posimer, had been approved by the Food and Drug Administration as a treatment for pain after a certain type of shoulder surgery. The drug is not an opioid. The company said that more than 600,000 arthroscopic subacromial decompression surgeries are performed in the U.S. each year. Durect's stock is up 9.4% over the past year, while the S&P 500 has gained 17.0%.